What did @tommydoesfitness_ actually say?
Not much, honestly. The transcript is six seconds of vague rebellion: "We're told we have to do we're told but surely sometimes you have to be a little bit naughty." Combined with hashtags like #tren and #peds, the implication is clear, he's on a first steroid cycle and framing it as harmless rule-breaking. There's no dosing claim, no specific compound named in speech, no health advice given. But the framing itself is the message.
The "naughty" framing is worth unpacking. It positions anabolic steroid use, specifically trenbolone based on the hashtag, as a minor social transgression, like eating cake on a diet. That's a significant misrepresentation of what the actual risk profile looks like. Trenbolone is not a beginner compound by any clinical or harm-reduction standard. When a 56,000-view video pairs this casual framing with #tren and #firstcycle in the same breath, the implicit endorsement carries weight even without explicit instructions.
Does the science back this up?
No. The "it's just a little naughty" framing has no scientific backing. Anabolic-androgenic steroid use, particularly with 19-nor compounds like trenbolone, is associated with a well-documented adverse effect profile that doesn't care how casual your attitude is.
A 2021 review by Sagoe et al. in the European Journal of Epidemiology estimated global lifetime AAS prevalence at around 6.4% in men, with adverse cardiovascular events among the most serious documented harms. Trenbolone specifically carries androgenic activity estimated at five times that of testosterone, with significant associations with left ventricular hypertrophy, dyslipidemia, and aggression documented in the literature (Shahidi, 2001, Clinical Biochemistry). A 2019 study by Baggish et al. in Circulation found that long-term AAS users had measurably worse left ventricular function compared to non-users, even years after stopping. "First cycle" status does not exempt someone from these risks. Cardiac remodeling can begin early, and trenbolone is not recommended even in harm-reduction communities as a first-time compound precisely because of its androgenic potency and psychological side effects.
What did they get wrong (or right)?
There's nothing factually incorrect stated outright, because almost nothing factual was stated. That's the problem. The video gets the vibe wrong, not a specific fact.
What's misleading is the normalization. Framing unsupervised trenbolone use as "being a little naughty" strips out the legitimate medical and safety context that even experienced users treat seriously. To the creator's credit, they didn't prescribe doses, didn't claim health benefits, and didn't push a product. That's a low bar, but it matters legally and ethically.
What they got wrong is the implied message: that first-cycle trenbolone is a casual, low-stakes decision. Harm-reduction organizations like AMEND (Academic Medical Education for Non-Dependent Drug Use) consistently recommend that if someone chooses to use AAS at all, they do so with bloodwork, cardiovascular monitoring, and ideally medical supervision. None of that culture is present in this framing. The casualness itself is the inaccuracy.
What should you actually know?
If you're considering any anabolic steroid use, including trenbolone, the "naughty" frame will not help you make a safe decision. Here's what the evidence actually says.
- Trenbolone is a veterinary-grade 19-nor compound with no approved human medical use. Its androgenic-to-anabolic ratio is approximately 500:500 compared to testosterone's 100:100 baseline (Shahidi, 2001).
- Cardiovascular risk is not hypothetical. Baggish et al. (2019, Circulation) found long-term AAS users had significantly reduced coronary flow reserve compared to non-users, a marker of impaired cardiac microvascular function.
- Psychiatric effects are real and underreported. A meta-analysis by Trenton and Currier (2005, CNS Drugs) documented increased aggression, mood instability, and in rare cases psychosis with high-potency androgens.
- Bloodwork before, during, and after any cycle is not optional for anyone taking this seriously. Lipid panels, hematocrit, liver enzymes, and hormone levels should all be tracked.
- Legitimate testosterone replacement therapy for diagnosed hypogonadism is a medically supervised protocol, not a gateway frame for recreational AAS use. The two are clinically distinct, and conflating them is inaccurate.
If you have questions about hormone therapy for a diagnosed condition, that conversation belongs with a licensed clinician who can review your labs, not a TikTok comment section.